Abstract
987P A phase Ib study of the PD-1 antagonist CS1003 plus lenvatinib (LEN) in Chinese patients (pts) with the first-line (1L) unresectable hepatocellular carcinoma (uHCC)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have